Jazz Pharmaceuticals

Diversified pharma

JAZZ · Nasdaq · Ireland

Share price · JAZZ

$247.77-5.30 (-2.09%) 3M

close as of 2026-11-18 · 24h delayed · vol 722K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when JAZZ's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026+7.1%
  2. 30 Oct 2026+3.9%
  3. 26 Oct 2026-3.9%
  4. 26 Aug 2026-4.2%
  5. 6 May 2026+7.7%
  6. 25 Feb 2026+13.2%

Share of unusual movement by asset

For each asset, the share of JAZZ's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zanidatamab
events and moves
2323%
Lurbinectedin
events and moves
103%
Cannabidiol (Epidiolex) (Epidiolex)
events and moves
6shown from 8 days
Dordaviprone
events and moves
4shown from 8 days
Cannabidiol (JZP926)
events and moves
1shown from 8 days
Calcium, magnesium, potassium and sodium oxybates (Xywav) (Xywav)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—28%
Sessions with no dated event—43%

Assets

(8 total)
8Total Assets
7Approved
0Phase 3 / Filed
1Phase 1–2 / Early
13Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
Approved
GABA-B receptorSmall molecule
NarcolepsyIdiopathic Hypersomnia
Approved
GPR55 / TRPV1 / adenosine transport (multi-target) · cannabinoidSmall molecule
EpilepsyDevelopmental and Epileptic EncephalopathiesDravet SyndromeLennox-Gastaut Syndrome
Approved
Mitochondrial caseinolytic protease P (ClpP) · Dopamine D2 receptorSmall molecule
Glioma
Approved
Alkylating DrugSmall molecule
Small Cell Lung Cancer
Approved
GABA-B receptorSmall molecule
Narcolepsy
Approved
DNA synthesis (cytarabine, antimetabolite) / Topoisomerase IISmall molecule
Acute Myeloid Leukemia
Approved
HER2Multispecific antibody
Non-Small Cell Lung CancerBiliary Tract CancerBreast CancerGastric Cancer
HER2-Positive Breast Cancer
Phase 2/3
Cannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55 · cannabinoidSmall molecule
Epilepsy

Discontinued programmes (2)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ZanidatamabPhase 2Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer …
Est. primary completion 2026-12-31 · NCT06695845 · CT.gov ↗
What to watch
2027 (3)
December 2027 (3)
Calcium, magnesium, potassium and sodium oxybates (Xywav)Phase 3Narcolepsy, Idiopathic Hypersomnia
Est. primary completion 2027-12-23 · NCT07625280 · CT.gov ↗
What to watch
ZanidatamabPhase 2HER2-positive Breast Cancer, Breast Cancer
Est. primary completion 2027-12-29 · NCT07102381 · CT.gov ↗
What to watch
LurbinectedinPhase 3Relapsed Small Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT06496048 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
LurbinectedinPhase 1/2Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Est. primary completion 2028-01-28 · NCT05734066 · CT.gov ↗
What to watch
April 2028 (1)
ZanidatamabPhase 3Metastatic HER2-positive Breast Cancer
Est. primary completion 2028-04-28 · NCT06435429 · CT.gov ↗
What to watch
June 2028 (1)
DordavipronePhase 3H3 K27M, Glioma
Est. primary completion 2028-06 · NCT05580562 · CT.gov ↗
What to watch
August 2028 (1)
Cannabidiol (JZP926)Phase 2/3Juvenile Myoclonic Epilepsy
Est. primary completion 2028-08-01 · NCT07723963 · CT.gov ↗
What to watch
December 2028 (1)
ZanidatamabPhase 3Biliary Tract Cancer
Est. primary completion 2028-12-01 · NCT06282575 · CT.gov ↗
What to watch
2029 (2)
August 2029 (2)
LurbinectedinPhase 2Extensive-stage Small-cell Lung Cancer
Est. primary completion 2029-08-04 · NCT07459634 · CT.gov ↗
What to watch
LurbinectedinPhase 3Leiomyosarcoma
Est. primary completion 2029-08-30 · NCT06088290 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(17)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026WithdrawalLurbinectedin (Zepzelca)FDA approves voluntary withdrawal of the Zepzelca second-line SCLC accelerated approval indication
US, FDA · Jazz Pharmaceuticals Ireland, Ltd. · Source ↗
31 August 2026Topline resultZanidatamabPhase 3 HERIZON-GEA-01 second interim analysis: ZIIHERA plus chemotherapy improved overall survival versus trastuzumab plus chemotherapy
25 August 2026ApprovalZanidatamabFDA approves Ziihera regimens in first-line HER2+ gastroesophageal adenocarcinoma
US, FDA · Source ↗
25 August 2026FDA action dateZanidatamabPDUFA target date August 25, 2026
US, FDA · Source ↗
3 August 2026Filing submittedCannabidiol capsule (JZP926)Jazz reports an NDA submitted for the cannabidiol capsule formulation in currently approved indications (reported 2026-08-03; submission date not disclosed)
US, FDA · Jazz Pharmaceuticals · Source ↗
August 2026ApprovalZanidatamabFDA updates Boxed Warning on Zanidatamab (BLA761416)
US, FDA · FDA · Source ↗
June 2026Topline resultLurbinectedinPhase 3 LAGOON did not meet its overall survival primary endpoint
27 April 2026Filing acceptedZanidatamabFDA accepts Ziihera sBLA for first-line HER2+ GEA
US, FDA · Source ↗
27 April 2026Priority reviewZanidatamabFDA grants Priority Review to Ziihera sBLA
US, FDA · Source ↗
7 October 2025FDA action dateLurbinectedinPDUFA date set for Zepzelca plus atezolizumab
US, FDA · Source ↗
2 October 2025ApprovalLurbinectedinFDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC
US, FDA · Source ↗
1 July 2025ApprovalZanidatamabEC conditional marketing authorization for Ziihera in HER2-positive BTC
EU, EC · Source ↗

The 12 most recent of 17 past events are shown.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.2B$212M$2.0B+ $820M short-term inv.$483M$506M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.2B$208M$1.6B+ $580M short-term inv.—$416M operating cash flowreport ↗
2026-Q1$1.1B$196M$1.8B+ $1.0B short-term inv.—$408M operating cash flowreport ↗
2025-Q3$1.1B$198M$1.3B—$475M operating cash flowreport ↗
2025-Q2$1.0B$190M$1.2B$718M$89M operating cash flowreport ↗
2025-Q1$898M$181M$1.9B$93M$430M operating cash flowreport ↗
2024-Q3$1.1B$200M$2.2B—$399M operating cash flowreport ↗
2024-Q2$1.0B$221M$1.4B—$331M operating cash flowreport ↗
2024-Q1$902M$223M$1.4B$15M$267M operating cash flowreport ↗
2023-Q3$972M$234M$1.3B—$307M operating cash flowreport ↗
2023-Q2$957M$209M$1.3B—$297M operating cash flowreport ↗
2023-Q1$893M$189M$1.2B—$321M operating cash flowreport ↗
2022-Q3$941M$149M$839M$20M$418M operating cash flowreport ↗
2022-Q2$933M$139M$711M—$303M operating cash flowreport ↗
2022-Q1$814M$130M$491M—$209M operating cash flowreport ↗
2021-Q3$838M$141M$672M$53M$274M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$4.3B$783M$1.4B+ $1.1B short-term inv.$89M$1.4B operating cash flowreport ↗

For FY2025, Jazz Pharmaceuticals reported revenue of $4,267.59M, up 4.9% YoY from $4,068.95M, with R&D spend of $782.74M, down 11.5% YoY. Cash and equivalents were $1,391.9M, and the company reported a net loss of $356.15M, with a quarterly net burn of $356.15M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$4.1B$884M$2.4B—$1.4B operating cash flowreport ↗
2023-FY$3.8B$850M$1.5B—$1.1B operating cash flowreport ↗
2022-FY$3.7B$590M$881M$56M$1.3B operating cash flowreport ↗
2021-FY$3.1B$506M$591M$82M$779M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 58 sales ($80.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06COZADD BRUCE C · directorOption exercise734$136.18$100KForm 4
2026-11-06COZADD BRUCE C · directorOption exercise85,766$136.18$11.7MForm 4
2026-11-06COZADD BRUCE C · directorOpen-market sale27,714$234.91$6.5MForm 4
2026-11-06COZADD BRUCE C · directorOpen-market sale10,688$235.82$2.5MForm 4
2026-11-06COZADD BRUCE C · directorOpen-market sale24,483$236.84$5.8MForm 4
2026-11-06COZADD BRUCE C · directorOpen-market sale5,923$237.39$1.4MForm 4
2026-11-06COZADD BRUCE C · directorOption exercise (derivative)734——Form 4
2026-11-06COZADD BRUCE C · directorOption exercise (derivative)85,766——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 566 reporting institutions held 65.0M shares ($11.5B, 103.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.5,591,700$1.1B
2VANGUARD PORTFOLIO MANAGEMENT LLC2,983,242$564.0M
3Capital World Investors2,673,376$505.4M
4VANGUARD CAPITAL MANAGEMENT LLC2,648,333$500.7M
5FMR LLC2,275,762$430.2M
6FRANKLIN RESOURCES INC1,958,940$370.3M
7DIMENSIONAL FUND ADVISORS LP1,895,215$358.3M
8STATE STREET CORP1,891,646$357.6M
9EcoR1 Capital, LLC1,706,469$322.6M
10Bank of New York Mellon Corp1,679,371$317.5M
11FULLER & THALER ASSET MANAGEMENT, INC.1,676,142$316.9M
12AMERIPRISE FINANCIAL INC1,608,476$304.1M
13AQR CAPITAL MANAGEMENT LLC1,338,458$249.9M
14MILLENNIUM MANAGEMENT LLC1,262,511$238.7M
15CITADEL ADVISORS LLC1,259,444$238.1M